Adults using Kalydeco (ivacaftor) or Trikafta (ivacaftor/tezacaftor/elexacaftor) to treat their cystic fibrosis (CF) showed gains in lung…
Articles by Patricia Inácio, PhD
The annual number of new cases of nontuberculous mycobacteria (NTM) lung infections is increasing in the U.S. among people with…
Two new Strategic Research Centres (SRC), each leading a multiyear study into research priorities identified by cystic fibrosis (CF)…
A new adrulipase formulation for people with cystic fibrosis (CF), designed as a treatment for exocrine pancreatic insufficiency or…
Children with cystic fibrosis (CF) who have normal pancreas function — called pancreatic sufficiency (PS) — are at higher…
Changes in two human voice parameters may help identify poor control of blood sugar levels in people with cystic…
Children and adolescents with cystic fibrosis (CF) commonly have procedural anxiety — a sudden and excessive fear of a…
The Phase 2 SPAN clinical trial of a new formulation of adrulipase in treating exocrine pancreatic insufficiency (EPI) in adults…
Monitoring the concentration of antibiotics in the blood — a clinical practice called therapeutic drug monitoring — was linked to…
Treatment with Orkambi (lumacaftor/ivacaftor) for six months lessened airway inflammation and enhanced airway bacterial diversity in people with cystic…